TrialClinical lung cancer2021

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).

Helena A Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.